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Systemic autoimmune disease in humans and mice is characterized by loss of immunologic 
tolerance to a restricted set of self-nuclear antigens. Autoantigens, such as double-stranded 
(ds) DNA and the RNA-containing Smith antigen (Sm), may be selectively targeted in 
systemic lupus erythematosus because of their ability to activate a putative common 
receptor. Toll-like receptor 9 (TLR9), a receptor for CpG DNA, has been implicated in the 
activation of autoreactive B cells in vitro, but its role in promoting autoantibody production 
and disease in vivo has not been determined. We show that in TLR9-deficient lupus-prone 
mice, the generation of anti-dsDNA and antichromatin autoantibodies is specifically 
inhibited. Other autoantibodies, such as anti-Sm, are maintained and even increased in 
TLR9-deficient mice. In contrast, ablation of TLR3, a receptor for dsRNA, did not inhibit the 
formation of autoantibodies to either RNA- or DNA-containing antigens. Surprisingly, we 
found that despite the lack of anti-dsDNA autoantibodies in TLR9-deficient mice, there was 
no effect on the development of clinical autoimmune disease or nephritis. These results 
demonstrate a specific requirement for TLR9 in autoantibody formation in vivo and indicate 
a critical role for innate immune activation in autoimmunity.
 
Systemic lupus erythematosus (SLE) is the
prototypical human autoimmune disease. Al-
though the underlying causes of SLE remain
unknown, the characteristic loss of immuno-
logic tolerance to a restricted set of self-nuclear
antigens is a common and defining feature of
disease (1–3). Autoantibodies to macromolec-
ular complexes of protein and nucleic acid,
such as chromatin and small nuclear ribonucle-
oproteins (snRNPs), are predominant in SLE
patients; antibodies directed against the indi-
vidual components of double-stranded (ds)
DNA, histones, and the several Smith antigen
(Sm) polypeptides can also be found in many
lupus patients (4–6). Because the ubiquitous
autoantigens targeted in SLE all contain some
form of nucleic acid, it is possible that the ca-
nonical antinuclear antibodies of lupus arise
because these autoantigens can stimulate invari-
ant receptors that recognize conserved nucleic
acid determinants (3).
Toll-like receptors (TLRs) are a class of
germline-encoded receptors that can be activated
by pathogen-associated molecular patterns. They
are essential for the generation of adaptive im-
mune responses against a wide variety of micro-
bial  components (7, 8). Recent evidence,
however, indicates that certain TLRs may also
be activated by nonmicrobial endogenous
ligands. TLR9, a receptor for hypomethylated
CpG DNA motifs (9), is expressed by B cells
in humans (10) and mice (9) and has been im-
plicated in the breakdown of immunologic
tolerance to self-nucleic acids in SLE. In vitro,
rheumatoid factor B cells proliferate in the
presence of chromatin-containing IgG im-
mune complexes; anti-dsDNA B cells similarly
respond to free chromatin. Both of these re-
sponses require signaling through TLR9 (11–13).
TLR3 is a receptor for dsRNA and is thought
to play a role in the immune response to RNA-
containing viruses (14). Although TLR3 has
not been directly linked to autoimmunity,
there is evidence that mRNA released from
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necrotic cells can activate signaling pathways downstream of
TLR3 (15). Moreover, the RNA-containing Sm and U1-
snRNP autoantigens contain stemloop and double-stranded
structures and may therefore represent endogenous TLR3
ligands (16). Such activation of TLR9 and TLR3 by the nu-
clear remnants of dying cells may focus the autoimmune re-
sponse on DNA and RNA antigens in lupus.
Despite several lines of intriguing in vitro data, there is as
of yet no direct in vivo evidence for a TLR-mediated mech-
anism of autoreactive B cell activation in SLE. Furthermore,
the relevance of TLR activation to autoimmune pathogenesis
and end organ disease has not been determined. In this re-
port, we have used the MRL/Mp
 
lpr/lpr
 
 murine lupus model to
investigate the requirements for TLR9 and TLR3 in autoan-
tibody production and clinical autoimmune disease. We find
that TLR9, but not TLR3, plays a critical role in determining
autoantibody specificity, as TLR9-deficient mice failed to
generate anti-DNA antibodies. However, the lack of TLR9
and resultant block of anti-DNA antibodies did not inhibit
clinical disease, indicating that multiple mechanisms, perhaps
mediated by other TLRs, contribute to SLE pathogenesis.
 
RESULTS
ANA profiles in TLR9- and TLR3-deficient mice
 
The inbred MRL/Mp mouse strain develops a lupus-like
syndrome marked by characteristic autoantibodies, dermati-
tis, nephritis, and early mortality, which are all accelerated in
the presence of the Fas
 
lpr/lpr
 
 mutation (17). To investigate the
role of TLR9 in autoimmune disease, we generated lupus-
prone TLR9-deficient (TLR9
 
 
 
/
 
 
 
) mice by making F2
crosses of TLR9
 
 
 
/
 
 
 
 mice and Fas-deficient MRL/Mp
 
lpr/lpr
 
mice. We selected those TLR9
 
 
 
/
 
 
 
 
 
 
 
 MRL/Mp
 
lpr/lpr
 
 F2 lit-
termates that were homozygous for Fas deficiency and either
wild-type TLR9 (TLR9
 
 
 
/
 
 
 
; 
 
n
 
 
 
 
 
 19) or TLR9
 
 
 
/
 
 
 
 (
 
n
 
 
 
 
 
 16)
mice. The heterogeneous genetic composition of the F2
generation was controlled with the use of large cohorts of
littermate controls such that background genes were evenly
divided between the two groups. Furthermore, the develop-
ment of autoimmunity in Fas-deficient mice has been docu-
mented on multiple genetic backgrounds (18). Similar
breeding strategies have been used previously to study the
effects of single genes on autoimmune disease (19, 20).
Because the fluorescent antinuclear antibody (ANA) as-
say is the most sensitive detection method for antibodies to a
variety of nuclear components in their native antigenic form
(21, 22), we used it as an initial measure of autoantibody
production in the serum of F2 mice. By classification of the
ANA staining pattern, we were able to determine the speci-
ficity of the autoimmune response and identify the dominant
autoantigens targeted by individual mice. Homogenous nu-
clear staining is known to correlate with anti-dsDNA anti-
bodies, whereas a coarsely speckled nuclear staining pattern
corresponds to antibodies directed against RNA-containing
antigens such as snRNPs or Sm (6, 23). Serum from 7 out of
Figure 1. TLR9-deficient sera lack anti-DNA and antichromatin 
staining patterns. (A) ANAs were determined in sera (1:200) from 20-wk-
old F2 mice. TLR9 /  sera are shown at the top (left, homogenous pattern; 
middle and right, speckled pattern); TLR9 /  sera are shown at the bottom 
(left and middle, speckled pattern; right, cytoplasmic pattern). Some 
TLR9 /  sera had predominantly speckled patterns superimposed on faint 
homogenous staining (middle). White arrows indicate cells in metaphase 
that demonstrate positive (top, TLR9 / ) or negative (bottom, TLR9 / ) 
chromatin staining. Original magnification, 400. (B) Digitally enlarged 
images of metaphase cells with positive (top, TLR9 / ) or negative (bottom, 
TLR9 / ) chromatin staining. (C) Serum ANAs were classified as nuclear 
homogenous, nuclear speckled, or cytoplasmic staining patterns. Black 
bars indicate TLR9 /  sera (n   19), and white bars indicate TLR9 /  sera 
(n   16). (D) As in C, but serum ANAs were classified as either positive or 
negative for mitotic chromatin staining. *, P   0.02; **, P   0.01; and
***, P   0.0001 by Fisher’s exact test. 
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19 TLR9
 
 
 
/
 
 
 
 mice exhibited homogenous nuclear staining,
whereas 0 out of 16 TLR9
 
 
 
/
 
 
 
 sera showed this pattern (Fig.
1, A and C; P 
 
 
 
 0.009, Fisher’s exact test), suggesting an im-
pairment in the generation of anti-dsDNA autoantibodies.
Moreover, equatorial staining of chromosomes in metaphase
cells, indicative of antichromatin antibodies, was observed in
17 out of 19 TLR9
 
 
 
/
 
 
 
 sera and 0 out of 16 TLR9
 
 
 
/
 
 
 
 sera
(Fig. 1, A, B, and D; P 
 
 
 
 0.0001). The high prevalence of
metaphase chromatin staining in TLR9
 
 
 
/
 
 
 
 sera presumably
reflects the presence of multiple different anti-DNA and an-
tinucleosome antibody specificities. TLR9
 
 
 
/
 
 
 
 mice were in-
capable of producing any of these autoantibodies.
In contrast to the lack of staining for anti-dsDNA and
antichromatin autoantibodies in TLR9
 
 
 
/
 
 
 
 sera, there was no
decrease in the proportion of mice with predominantly
speckled ANA patterns, though TLR9
 
 
 
/
 
 
 
 sera had a qualita-
tively different speckled pattern compared with TLR9
 
 
 
/
 
 
 
sera. Although wild-type sera demonstrated mixed speckled
and homogenous staining, TLR9
 
 
 
/
 
 
 
 sera had exclusively
speckled patterns in the absence of any superimposed ho-
mogenous staining (Fig. 1 A and not depicted). In addition,
TLR9
 
 
 
/
 
 
 
 sera had an increased incidence of primarily cyto-
plasmic staining compared with wild-type littermates (Fig. 1,
A and C; P 
 
 
 
 0.013), although the sera with cytoplasmic
patterns also stained nuclei in a faint speckled pattern. These
findings indicate that TLR9
 
 
 
/
 
 
 
 mice were capable of target-
ing the typical RNA-containing autoantigens of lupus and
account for the equivalence of quantitative ANA titers in the
two groups of mice (median titer 
 
 
 
1:2,000; unpublished
data). Furthermore, the distribution of ANA patterns in
TLR9
 
 
 
/
 
 
 
 mice suggests that in the absence of anti-DNA an-
tibodies, other autoantibody specificities are maintained and
may even become more prominent.
TLR3-deficient lupus-prone mice were generated by F2
crosses with MRL/Mp
 
lpr/lpr
 
 mice in an analogous fashion to
TLR9 mice. Unlike the TLR9 cohort, there was no differ-
ence in the distribution of either homogenous or speckled
nuclear ANA patterns between TLR3
 
 
 
/
 
 
 
 (
 
n
 
 
 
 
 
 15) and
TLR3
 
 
 
/
 
 
 
 (
 
n
 
 
 
 
 
 17) littermates (Fig. 2, A and C). In addition,
nearly all mice in both groups produced antibodies to chro-
matin, as evidenced by bright staining of metaphase chromo-
somes in mitotic cells (Fig. 2, A, B, and D). Because TLR3 is
a receptor for dsRNA and may be involved in the generation
of autoantibodies to RNA-containing antigens, we examined
speckled ANA staining patterns in TLR3
 
 
 
/
 
 
 
 sera but could
detect no difference in either the quality or intensity of stain-
ing for RNA-containing antigens. Both TLR3
 
 
 
/
 
 
 
 and
TLR3
 
 
 
/
 
 
 
 mice produced autoantibodies that stained nuclear
substrates with fine speckled, discrete speckled, and mixed
speckled/homogenous patterns (Fig. 2 A and not depicted).
Based on the ANA, the autoantibody profile of TLR3
 
 
 
/
 
 
 
mice was thus indistinguishable from wild-type littermates.
 
Lack of anti-dsDNA autoantibodies in TLR9-deficient mice
 
The loss of homogenous nuclear and mitotic chromatin
staining in TLR9
 
 
 
/
 
 
 
 sera implied a block in the generation
of autoantibodies to DNA-containing antigens; thus, we
sought to confirm this with a specific assay for anti-dsDNA
Figure 2. Unaltered ANA patterns in TLR3-deficient sera. (A) Serum 
ANAs were determined as in Fig. 1. TLR3 /  sera are shown at the top 
(left, homogenous pattern; middle and right, speckled pattern); TLR3 /  
sera are shown at the bottom (left, homogenous pattern; middle and 
right, speckled pattern). White arrows indicate cells in metaphase that 
demonstrate positive chromatin staining. Original magnification, 400. 
(B) Digitally enlarged images of metaphase cells with positive chromatin 
staining. (C) Serum ANAs were classified as nuclear homogenous, nuclear 
speckled, or cytoplasmic staining patterns. Black bars indicate TLR3 /  
sera (n   15), and white bars indicate TLR3 /  sera (n   17). (D) As in C, 
but serum ANAs were classified as either positive or negative for mitotic 
chromatin staining. 
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antibodies. Indirect immunofluorescence on 
 
Crithidia luciliae
 
substrates is an established assay for the detection of anti-
dsDNA autoantibodies in SLE (24). Because the kinetoplast
organelle of 
 
C. luciliae
 
 is composed exclusively of circular ds-
DNA in the absence of single-stranded (ss) DNA, RNA, or
histones, the 
 
C. luciliae
 
 assay is clinically the most specific test
for antibodies to native dsDNA (25, 26). To further enhance
the detection of anti-DNA antibodies, we costained the 
 
C.
luciliae
 
 DNA with DAPI, thus permitting the differentiation
of irrelevant cytoplasmic structures from true staining of ki-
netoplast and nuclear dsDNA (Fig. 2 A).
Among the TLR9 F2 mice, a subset of TLR9
 
 
 
/
 
 
 
 sera
contained specific anti-dsDNA antibodies as detected by
strong staining of the 
 
C. luciliae
 
 kinetoplast, but these antibod-
ies were absent in sera from TLR9
 
 
 
/
 
 
 
 mice (Fig. 3, A and B;
P 
 
 
 
 0.0121, Mann-Whitney U test). 7 out of 19 wild-type
and 3 out of 16 TLR9
 
 
 
/
 
 
 
 sera were also found to have bor-
derline staining of dsDNA, as evidenced by a faint ring around
the kinetoplast (intensity score, 1; Fig. 3, A and B). It was un-
clear whether these staining patterns represented low-affinity
anti-dsDNA or nonspecific antibodies. We therefore analyzed
the incidence of anti-dsDNA using intensity scores of either
 
 0 or  1 as positive. With both methods of analysis, we ob-
served a significant reduction in anti-dsDNA antibodies in
TLR9 /  sera (P   0.05, Fisher’s exact test). In contrast,
TLR3 /  mice appeared to have no impairment in the gener-
ation of anti-dsDNA autoantibodies, as there was no differ-
ence in the incidence or intensity of kinetoplast staining be-
tween TLR3 /  and TLR3 /  sera (Fig. 3 C). Thus, TLR9,
but not TLR3, was required for the generation of specific au-
toantibodies to dsDNA in the context of murine lupus.
Anti-Sm and anticardiolipin autoantibodies 
in TLR-deficient mice
Autoantibodies to Sm are exclusive to SLE and occur in
 25% of diseased humans and mice (27, 28). We performed
Western blots to detect antibodies against the protein compo-
nents of the Sm complex. Mice in both the TLR9 and TLR3
F2 cohorts generated antibodies reacting with a cluster of
bands in the 29–34-kD region of the gel, corresponding to
the complex of B and B  proteins (Fig. 4, A and B). As ex-
pected, TLR9 /  mice produced anti-Sm autoantibodies. In
fact, there was a significant increase in the proportion of
TLR9 /  mice with anti-Sm reactivity compared with
TLR9 /  littermates (Fig. 4, A and C; P   0.0049, Fisher’s
exact test). We confirmed these findings with a solid phase
ELISA using purified whole Sm antigen as the target and
again found higher levels of anti-Sm autoantibodies in
TLR9 /  mice (Fig. 4 D; P   0.0014, Mann-Whitney U
test). Consistent with the presence of speckled ANA patterns,
TLR3 /  mice also generated anti-Sm autoantibodies at fre-
quencies equivalent to their wild-type counterparts (Fig. 4,
B, C, and E). Thus, neither TLR9 nor TLR3 was required
for the production of autoantibodies to the RNA-containing
Sm antigen, even though, unexpectedly, there was a relative
increase in anti-Sm autoantibodies in TLR9 /  mice.
Antiphospholipid antibodies are also commonly found in
autoimmune disease and are associated with coagulation ab-
normalities and thrombosis (6). Because of the polyanionic
nature of the lipid antigen, antiphospholipid antibodies can
cross-react with DNA, and anti-DNA antibodies can like-
wise have dual specificity for lipids such as phosphati-
dylserine (29). To determine if TLR9 deficiency or the loss
of anti-dsDNA antibodies in TLR9 /  mice affected the
generation of antiphospholipid antibodies, we measured au-
toantibodies to cardiolipin, a prototypical phospholipid anti-
gen. We found that TLR9 /  mice developed serum titers
of anticardiolipin antibodies that were comparable to
TLR9 /  littermates (Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20050338/DC1), indicating that
anti-dsDNA and antiphospholipid antibodies are controlled
by separate mechanisms in these mice.
Figure 3. Reduced anti-dsDNA autoantibodies in TLR9 /  but not 
TLR3 /  mice. (A) Anti-dsDNA antibodies were detected by C. luciliae 
immunofluorescence. IgG antibodies to C. luciliae DNA are shown in green 
(left), and DAPI staining of DNA is shown in red (middle). White arrows 
indicate the kinetoplast. Specific anti-dsDNA antibodies are identified by 
colocalization of IgG and DAPI staining in the kinetoplast and appear in 
yellow (right). Representative TLR9 /  sera are shown in the top two rows 
(intensity scores of 3  and 1 ), and TLR9 /  sera are shown in the bottom 
two rows (intensity scores of 1  and 0). Original magnification, 1,000. 
(B and C) Specific anti-dsDNA staining of C. luciliae kinetoplasts was scored 
from 0 to 4 as in A for either TLR9 /  (n   19) and TLR9 /  (n   16) sera 
(B), or TLR3 /  (n   15) and TLR3 /  (n   17) sera (C). *, P   0.02 by the 
Mann-Whitney U test.JEM VOL. 202, July 18, 2005 325
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Global immune activation in TLR-deficient lupus-prone mice
Antichromatin and antiribonucleoprotein antibodies are
among the earliest detectable autoantibodies in SLE and are
known to precede the appearance of overt clinical disease in
both humans and mice (30, 31). The breakdown of toler-
ance to DNA-containing antigens may thus be a critical first
step in systemic autoimmunity, and the early appearance of
antichromatin autoantibodies may facilitate disease progres-
sion and epitope spreading to other nuclear autoantigens
(32). We therefore determined whether the lack of TLR9 or
TLR3 had any effect on several parameters of global autoim-
mune disease. TLR-intact and TLR-deficient mice from
both the TLR9 and TLR3 cohorts exhibited massive lym-
phadenopathy and splenomegaly (Fig. 5 A), characteristic of
the accumulation of activated lymphocytes in Fas-deficient
autoimmunity. Both groups of mice also had elevated levels
of total IgG and IgG2a in the serum relative to nonautoim-
mune C57BL/6 mice (Fig. 5 B). To further define the au-
toimmune phenotype, we enumerated T cells, B cells, and
CD4 /CD8  double-negative T cells, which accumulate
with age in MRL/Mplpr/lpr mice (17). These cell populations
were not decreased in TLR-deficient mice in the spleen
(Fig. 5 C) or lymph nodes (unpublished data), nor was there
any block in the accumulation of activated and memory
phenotype CD4  T cells (Fig. 5 D). Thus, neither deficiency
of TLR9 or TLR3 nor the specific absence of anti-DNA
autoantibodies in TLR9 /  mice inhibited the disregulated
immune activation and aberrant lymphocyte accumulation
of systemic autoimmune disease.
There was, however, an unexpected increase in immune
activation in TLR9 /  animals compared with wild-type lit-
termates. This was not observed for animals in the TLR3
cohort. Lymph node weight (P   0.0016), splenic T cell
count (P   0.0277), double-negative T cell count (P  
0.0150), and activated CD4  T cell count (P   0.0327)
were all significantly greater in TLR9 /  mice compared
with TLR9 /  littermates. Because the vast majority of the
lymph node in these animals is composed of activated and
double-negative T cells (unpublished data), these findings all
point toward an increased level of T cell activation in
TLR9-deficient mice.
In addition to hypergammaglobulinemia and the accu-
mulation of activated lymphocytes, increased production of
type I IFNs is associated with SLE in humans and mice (33–
35). Moreover, genetic ablation of the type I IFNR mark-
edly reduced clinical and immunologic signs of lupus in
New Zealand Black mice (36), although this was not ob-
served in other autoimmune strains (37). Because activation
of TLR9 and TLR3 is known to stimulate the secretion of
type I IFNs (38, 39), we determined whether lack of either
of these receptors influenced spontaneous IFN levels in au-
toimmune mice. Using an ELISA to detect serum IFN- ,
we could not detect any impairment in IFN production by
TLR9 /  or TLR3 /  F2 mice (unpublished data). Al-
though the sensitivity of this assay was limited to IFN- , it
was clear that a subset of mice exhibited markedly elevated
levels type I IFNs even in the absence of TLR9 or TLR3.
Glomerulonephritis and immune complex deposition in the 
absence of anti-DNA autoantibodies
To assess renal disease in TLR9- and TLR3-deficient au-
toimmune mice, we first measured spot proteinuria at the
time of sacrifice. There was no difference between TLR9 / 
or TLR3 /  mice and their wild-type counterparts, with
most mice exhibiting mild to moderate levels of proteinuria
(unpublished data). Histologically, interstitial and perivascu-
lar lymphocytic infiltrates were present in the kidneys of all
mice. There was a moderate increase in glomerular size and
Figure 4. Presence of anti-Sm autoantibodies in TLR-deficient 
mice. (A) Anti-Sm antibodies were detected by Western blot in TLR9 /  
(WT; n   19) and TLR9 /  (KO; n   16) sera. The monoclonal anti-Sm 
antibody Y12 was used as a positive control. Depicted portion of the gel 
is from 29–34 kD, corresponding to the B and B  cluster of Sm proteins. 
(B) Anti-Sm antibodies were detected in TLR3 /  (WT; n   15) and TLR3 /  
(KO; n   17) sera as in A. Nonautoimmune control sera are also depicted 
(neg; n   4). (C) Sera from TLR9 and TLR3 cohorts was scored as either 
positive or negative for anti-Sm antibodies by Western blot as in A and B. 
(D and E) Anti-Sm antibodies were confirmed by ELISA in either TLR9 /  
(n   19) and TLR9 /  (n   16) sera (D), or TLR3 /  (n   15) and TLR3 /  
(n   17) sera (E). Bars represent median values. *, P   0.005 by Fisher’s 
exact test (C) or the Mann-Whitney U test (D).TLR9 CONTROLS ANTI-DNA AUTOANTIBODIES | Christensen et al. 326
cellularity, with no detectable difference in any parameter
between TLR9 /  and TLR9 /  (Fig. 6, A, C, and E) or
TLR3 /  and TLR3 /  mice (Fig. 6, G, I, and K). Periodic
acid Schiff (PAS) staining of kidney sections further revealed
that TLR9 /  (Fig. 6, B, D, and F) and TLR3 /  (Fig. 6,
H, J, and L) mice developed substantial glomerular protein
deposition that was comparable to wild-type littermates,
with marked thickening of capillary loops and obliteration of
Figure 5. Lymphadenopathy, hypergammaglobulinemia, and lym-
phocyte accumulation in TLR-deficient mice. TLR9 /  (n   19), TLR9 /  
(n   16), TLR3 /  (n   15), and TLR3 /  (n   17) mice were killed at 
20 wk of age and assessed for evidence of aberrant immune activation; 
nonautoimmune C57BL/6 control mice (n   4) were killed at 26 wk of age. 
(A) Spleens and the two largest axillary lymph nodes were removed and 
weighed. (B) Total serum IgG and IgG2a were determined. (C) Splenocyte 
subsets were enumerated by FACS analysis for T cells (Thy1.2 ), DNTC 
(CD4 /CD8  double-negative T cells), and B cells (CD22 ). (D) Splenic 
CD4  T cells were classified as either naive (CD44  CD62L ), activated 
(CD44  CD62L ), or memory (CD44  CD62L ) phenotype. The analysis in 
D was performed on 12 TLR3 /  and 12 TLR3 /  mice. Horizontal lines 
represent mean values.
Figure 6. Glomerulonephritis in the absence of anti-DNA autoanti-
bodies. Histological renal disease was assessed in TLR9 /  (n   19), 
TLR9 /  (n   16), TLR3 /  (n   15), and TLR3 /  (n   17) mice at 20 wk 
of age. (A–F) Paraffin kidney sections from TLR9 /  (A and B) and TLR9 /  
(C and D) mice were stained with H&E (A and C) or PAS (B and D). Intersti-
tial infiltrates (E) and glomerular disease (F) were scored from 0 to 4 for all 
mice. (G–L) Paraffin kidney sections from TLR3 /  (G and H) and TLR3 /  
(I and J) mice were stained with H&E (G and I) or PAS (H and J). Interstitial 
infiltrates (K) and glomerular disease (L) were scored from 0 to 4 for all 
mice. Representative images are shown. Original magnification: 100 for 
H&E sections (A, C, G, and I) and 400 for PAS sections (B, D, H, and J).JEM VOL. 202, July 18, 2005 327
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vessel lumens. These findings indicate that neither TLR9
nor TLR3 was essential for the induction of end organ dis-
ease in murine lupus.
Although interstitial renal disease and glomerulonephritis
were not inhibited in TLR9-deficient mice, it was unclear
whether this was caused by direct glomerular deposition of
immunoglobulin and complement-containing immune com-
plexes. We therefore assessed renal IgG and complement
deposition in TLR9 /  mice lacking anti-dsDNA and anti-
chromatin autoantibodies. Both TLR9 /  and TLR9 / 
mice had immune deposits throughout the glomerulus, in
contrast to nonautoimmune C57BL/6 mice (Fig. 7 A). Al-
though levels of IgG and C3 deposition varied among indi-
viduals, there was no difference in the mean glomerular fluo-
rescence between the two groups of mice (Fig. 7 B). Thus,
lupus nephritis and glomerular immune complex deposition
were unaffected by the absence of anti-dsDNA and antichro-
matin autoantibodies in autoimmune TLR9 /  mice.
DISCUSSION
Since the initial report of a role for TLR9 in the activation
of autoreactive B cells in vitro (11), there has been intense
interest and speculation about the importance of TLRs for
autoantibody production and clinical disease in SLE. Our
findings represent the first demonstration that a TLR is re-
quired for specific autoantibody production in vivo. We
found that TLR9, but not TLR3, was necessary for the gen-
eration of specific autoantibodies to chromatin and dsDNA
in the context of murine lupus. The control of these autoan-
tibodies by TLR9 indicates the central role of this receptor
in systemic autoimmune diseases such as SLE, in which
ANAs are a cardinal feature. Because of inherent limitations
in the determination of autoantibody specificity, however,
we could not completely exclude the presence of low-affin-
ity or cross-reactive antibodies to DNA in TLR9 /  mice,
which may arise by TLR9-independent mechanisms.
The requirement for TLR9 in anti-DNA antibody pro-
duction was surprising because TLRs are thought to dis-
criminate self from nonself by recognizing only pathogen-
associated molecular patterns not present on mammalian cells.
However, mounting evidence suggests that innate receptors
such as TLR9 exhibit some degeneracy of ligand binding.
Synthetic oligonucleotides containing methylated DNA or
lacking canonical CpG activation motifs have both been
shown to stimulate B cells in the presence of concurrent B
cell receptor (BCR) stimulation (40, 41), and murine geno-
mic DNA can induce APC activation both in vitro and in
vivo (42). More relevant to autoimmunity, chromatin–anti-
chromatin immune complexes provide a potent activation
stimulus to dendritic cells and autoreactive rheumatoid factor
B cells, both of which require TLR9 for complete stimula-
tion (11, 13, 43).
Why are TLRs that can recognize self-antigens not con-
stitutively activated? One important control mechanism ap-
pears to derive from intracellular compartmentalization. Nor-
mally, activation of TLR9 by endogenous nucleic acids may
be inhibited because the receptor is sequestered in the endo-
somal pathway (44), where host-derived nuclear antigens are
largely excluded. Other TLRs that bind nucleic acid ligands
are similarly segregated in endosomal compartments (8).
However, because anti-DNA B cells are uniquely poised to
endocytose and deliver DNA-containing antigens (via the
BCR) to TLR9 in restricted intracellular compartments, the
spatial separation of TLR9 from inappropriate self-ligands
may break down in these cells. This phenomenon could ex-
plain the selective tolerance breakdown of antinuclear B cells
in autoimmunity and the highly restricted autoantibody rep-
ertoire of SLE. Such a mechanism of BCR-mediated en-
docytosis also suggests a B cell–intrinsic requirement for
TLR9 costimulation. In vitro studies using rheumatoid factor
and anti-DNA B cells have confirmed this two signal model
of autoreactive B cell activation through both BCR and
TLR9 signaling pathways (12).
Introduction of TLR9 ligands to restricted compart-
ments may also occur when mechanisms for clearance of ap-
optotic cell debris are overwhelmed. Apoptotic cells are re-
positories of lupus autoantigens (45), and there is evidence
that residual fragments of apoptotic DNA have a greater
stimulatory capacity than native genomic DNA (12). Further
support for innate immune activation by the products of cell
death comes from studies of genetic ablation of DNaseII, a
Figure 7. Glomerular immune deposits do not require anti-DNA 
antibodies. (A) Glomerular immune deposits were detected by direct 
immunofluorescence for IgG (top) and complement C3 (bottom) in frozen 
kidney sections from TLR9 /  (left), TLR9 /  (middle), and nonautoimmune 
C57BL/6 control mice (right). Representative images are shown. Original 
magnification, 400. (B) Mean glomerular fluorescence intensity (arbitrary 
units) was determined for IgG and C3 in TLR9 /  (n   8) and TLR9 /  
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lysosomal endonuclease required for digestion of apoptotic
DNA fragments by macrophages. In Drosophila, DNaseII de-
ficiency results in dysregulated expression of antibacterial
gene products (46), whereas in mice, the accumulation of
residual DNA induces IFN-  secretion by fetal liver mac-
rophages, inhibition of hematopoiesis, and resultant embry-
onic lethality (47). The development of autoimmunity in
mice with impaired phagocytosis of apoptotic cells (48) and
in humans and mice lacking the early components of com-
plement (49) provides additional evidence for a model of
tolerance breakdown initiated by inappropriate innate rec-
ognition of apoptotic or necrotic debris.
In contrast to the absence of anti-dsDNA and antichro-
matin, we found an increased incidence of anti-Sm autoanti-
bodies in TLR9-deficient mice relative to wild-type litter-
mates. This could be the result of several factors. For instance,
TLR9 /  mice may have developed a compensatory increase
in levels of autoantibodies to RNA-containing antigens as a
direct result of the loss of anti-DNA antibodies. If the “im-
munizing” antigens in SLE derive from apoptotic debris and
antinuclear antibodies can aid in the clearance of these parti-
cles, then the lack of anti-DNA antibodies in TLR9 /  mice
could lead to a marked increase in circulating levels of au-
toantigens. In this situation, when the presumably dominant
epitopes of DNA and chromatin are rendered nonimmuno-
genic, alternate epitopes such as Sm, snRNPs, and cytoplas-
mic antigens may become more prominent, as observed in
TLR9 /  sera. Alternatively, the increase in anti-Sm anti-
bodies may reflect competition and reciprocal suppression
among different TLRs. Activation of various TLRs is known
to inhibit subsequent responses by TLRs that share down-
stream signaling pathways (50), and stimulation of TLR9 by
endogenous DNA may therefore prevent responses to other
TLR ligands. Because it is probable that other TLRs control
the autoantibody response to RNA antigens (as will be dis-
cussed), the removal of TLR9-mediated inhibition may allow
these alternate mechanisms of autoantibody production to
proceed unchecked. Finally, the increase in anti-Sm titers
among TLR9 /  mice may reflect an increased severity of
autoimmune disease, as suggested by the trend toward in-
creased accumulation of activated T cells in these mice.
Unlike TLR9, TLR3 had no role in the generation of
autoantibodies to DNA or the prototypical RNA-contain-
ing Sm antigen. One potential explanation for this is the
highly restricted cellular expression of TLR3. TLR3 expres-
sion has only been detected in mature dendritic cells of the
myeloid lineage (51), and was not observed in B cells by
quantitative PCR (52). It is also possible that the specificity
of TLR3 for dsRNA is not appropriate for the prototypical
RNA-containing autoantigens of lupus, which are com-
posed primarily of ssRNA alternating with regions of intra-
strand base pairing. Another candidate for the regulation of
autoantibodies to RNA antigens is TLR7, which has re-
cently been identified as an innate receptor for ssRNA (53,
54). TLR7 is closely related to TLR9 in protein sequence
and downstream signaling pathways (7), and, like TLR9, is
expressed on B cells in endosomal compartments (8, 52).
Other innate receptors capable of recognizing microbial
RNA may also promote anti-RNA antibodies in SLE.
These include the protein kinase regulated by RNA (55),
TLR8 in humans (54), and, potentially, additional RNA re-
ceptors not yet identified (56, 57).
Although TLR9 can shape the autoantibody repertoire in
SLE, lack of either TLR9 or TLR3 did not ameliorate clini-
cal disease in lupus-prone mice. This was particularly surpris-
ing given the prevailing view that anti-dsDNA and antichro-
matin antibodies are principal mediators of renal pathology in
SLE (2, 58). Although it is clear that anti-DNA antibodies are
associated with nephritis (5), are found deposited in diseased
kidneys (59), and can mediate nephritis in adoptive transfer
experiments (60), there is an accumulating body of evidence
to suggest that other autoantibody specificities can play
equally prominent roles. Anti-Sm antibodies, for example,
are also correlated with renal disease in clinical studies (61),
and the elevated titers of anti-Sm antibodies in TLR9 / 
mice may account for the persistence of nephritis and im-
mune deposits in the absence of anti-dsDNA. A definitive
experiment using NZM congenic mice further demonstrated
that severe, chronic glomerulonephritis with early mortality
could occur in the absence of any detectable ANA, including
anti-DNA antibodies (62). Our data thus provide a novel
demonstration of a previously observed finding: although
anti-dsDNA autoantibodies may predict nephritis in SLE,
they are not the exclusive pathogenic specificity. Finally, it
remains possible that disease occurs in the absence of anti-
dsDNA because autoantibodies by themselves are not re-
quired for target organ disease, and autoreactive B cells exert
pathogenic effects independent of antibody secretion (63).
Given the potential of TLR9 to recognize endogenous
DNA and the inherent predisposition toward anti-DNA re-
activity in the germline V gene repertoire of the BCR (64),
it is unclear why this dual propensity for self-reactivity
should coexist in the same cell. It is possible that self-reactiv-
ity and the rare occurrence of anti-DNA antibodies are the
unavoidable byproduct of an essential defense against patho-
genic microorganisms. It is also possible, however, that TLR
stimulation could lead to regulatory or even antiinflamma-
tory effects in certain contexts. For example, the ability of
TLR stimulation to promote homeostatic repair processes
without the induction of an inflammatory or adaptive im-
mune response was recently demonstrated in a model of in-
duced intestinal injury (65). Similarly, the regulated produc-
tion of low-affinity anti-DNA IgM antibodies in the absence
of infection may facilitate clearance of dying cells, limit inap-
propriate inflammation, and suppress autoimmune disease.
Thus, the increased lymphadenopathy and T cell activation
observed in lupus-prone TLR9 /  mice may be caused by
the lack of a protective subset of anti-DNA antibodies. Con-
sistent with this idea, the absence of secreted IgM in lupus-
prone mice exacerbates autoantibody formation, disease ac-
tivity, and mortality (66). An analogous role for physiologic
rheumatoid factor autoantibodies has been postulated, asJEM VOL. 202, July 18, 2005 329
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these “natural” anti-IgG antibodies promote clearance of
immune complexes in conditions of high antigenic burden
(67, 68). The intriguing possibility that TLR-mediated cel-
lular activation and autoantibody production could enhance
the clearance of apoptotic cell debris, promote tissue repair
or limit autoimmune pathology remains to be investigated.
Regardless of the exact roles of anti-dsDNA and antichro-
matin antibodies in promoting or regulating disease, the dem-
onstration that TLR9 controls these canonical autoantibodies
of SLE represents an important advance in our understanding
of the mechanisms of systemic autoimmunity. The pathologic
immune response of autoimmune disease, like the adaptive
immune response to foreign antigens, may fundamentally re-
quire instruction by the innate immune system. Although
prevention of anti-dsDNA and antichromatin autoantibody
production did not ameliorate clinical disease, inhibition of
TLRs or other innate signaling pathways may yet provide
new therapeutic targets in the treatment of human lupus. This
will require a more complete understanding of the complete
complement of innate immune receptors and their individual
roles in the pathogenesis of autoimmune disease.
MATERIALS AND METHODS
Mice. Heterozygous TLR9 /  mice (9) of a mixed genetic background
(B6 and 129Sv) were bred to MRL/Mplpr/lpr mice in our colony under spe-
cific pathogen-free conditions. Intercrossing of F1 offspring in five matings
produced 22 Fas-deficient (Faslpr/lpr) F2 mice, 5 of which were TLR9 / 
and 4 of which were TLR9 / . Intercrossing of heterozygous TLR9 /  F2
mice in four additional matings produced 56 Faslpr/lpr mice, 15 of which
were TLR9 /  and 13 of which were TLR9 / . The genetic composition
of both generations of mice was  50% MRL/Mp. One mouse in each
group died before planned analysis at 19–21 wk of age. In a separate cohort,
homozygous TLR3 /  mice (14) of a mixed genetic background (B6 and
129Sv) were bred to MRL/Mplpr/lpr mice as above. Intercrossing of F1 off-
spring in nine matings produced 33 Faslpr/lpr mice, 9 of which were TLR3 / 
and 11 of which were TLR3 / . Intercrossing of heterozygous TLR3 / 
F2 mice in three additional matings produced 26 Faslpr/lpr mice, 8 of which
were TLR3 /  and 6 of which were TLR3 / . Two TLR3 /  mice died
before planned analysis at 19–21 wk of age. C57BL/6 mice (Charles River
Laboratories) were maintained in our mouse colony to an age of 26 wk. All
animal studies were conducted in accordance with protocols approved by
the Yale University Institutional Animal Care and Welfare Committee.
ANA and anti-dsDNA immunofluorescence. Serum was obtained via
retroorbital puncture just before death. For ANA, serum was diluted 1:200
and used for indirect immunofluorescence on fixed Hep-2 ANA slides (An-
tibodies Inc.) with fluorescein-conjugated goat anti–mouse IgG (Southern
Biotechnology Associates, Inc.) as the detection reagent. Slides were read
on a fluorescent microscope (BX-40; Olympus) at 400  and scored as ei-
ther nuclear homogenous, nuclear speckled, or cytoplasmic staining patterns
by a reader blinded to the genotype of the mice. In addition, each serum
sample was scored for staining of mitotic chromosomes. Images were cap-
tured with a cooled CCD camera (Spot-RT Slider; Diagnostic Instruments)
with a constant exposure time of 4 s for TLR9 sera and 2.5 s for TLR3 sera.
For TLR9 F2 mice, endpoint titration of serum was performed at reciprocal
dilutions of 50, 200, 800, 2,000, 104, 4   104, and 105, and samples were
scored for the presence of nuclear staining, regardless of pattern or cytoplas-
mic staining. Serum samples from 26-wk-old C57BL/6 mice were negative
for ANA at 1:50 dilution (unpublished data).
For anti-dsDNA, 1:10 diluted serum was applied to fixed C. luciliae
slides (Antibodies Inc.), with biotin-conjugated goat anti–mouse IgG
(Southern Biotech) and Alexa Fluor 555–conjugated streptavidin (Molecu-
lar Probes) as detection reagents. C. luciliae DNA was colocalized with
DAPI (Molecular Probes). Slides were read at 1,000  and scored 0–4 for
intensity of kinetoplast staining by a reader blinded to the genotype of the
mice. Images were captured with a constant exposure time of 0.5 s in red
(IgG) and blue (DAPI) channels, and then transferred into green (IgG) and
red (DAPI) channels.
Anti-Sm Western blot and ELISA. For Western blot, purified bovine
Sm antigen (Immunovision) was separated by SDS-PAGE, transferred to ni-
trocellulose membrane, and probed with 1:200 diluted serum, using alkaline
phosphatase-conjugated goat anti–mouse IgG (Southern Biotech) and
BCIP/NBT substrate (KPL, Inc.) as detection reagents. The monoclonal
mouse anti-Sm antibody Y12 (28) was used as a standard. Blots were scored
for the presence of visible anti-Sm bands at 29–34 kD. For ELISA, polysty-
rene plates were coated with Sm antigen, blocked with 1% BSA in PBS,
and serial dilutions of serum from 1:50 to 1:36,450 were added. Anti-Sm
antibodies were detected with alkaline phosphatase-conjugated goat anti–
mouse IgG (Southern Biotech), and absorbance at 405/630nm was com-
pared with the Y12 standard to quantitate.
Anticardiolipin ELISA. Polystyrene plates were coated with cardiolipin
by incubation with 100  g/ml bovine cardiolipin (Avanti Polar Lipids,
Inc.) in 100% ethanol for 12–18 h at 4 C until completely evaporated.
Plates were blocked with 1% BSA in PBS, and serial dilutions of serum
from 1:100 to 1:2,700 were added. Anticardiolipin antibodies were detected
with alkaline phosphatase–conjugated goat anti–mouse IgG (Southern Bio-
tech), and absorbance at 405/630 nm was compared with the FD1 standard
to quantitate. Anticardiolipin standards were provided by M. Monestier
(Temple University School of Medicine, Philadelphia, PA).
Analysis of lymphocyte subsets and serum IgG. Spleen and lymph
node cells were isolated, counted, and stained with the following antibodies
for fluorescence-activated cell sorting analysis: anti-Thy1.2 (30H12), anti-
CD4 (GK1.5), anti-CD8 (TIB105), anti-CD44 (IM7), anti-CD62L (Mel-
14), and anti-CD22.2 (Cy34.1). All antibodies except anti-CD22.2 (BD
Biosciences) were made in our laboratory. Total serum IgG and IgG2a were
determined by ELISA. Polystyrene plates were coated with goat anti–mouse
IgG (Southern Biotech), blocked with 1% BSA in PBS, and serial dilutions
of serum from 1:104 to 1:7.3   106 were added. IgG or IgG2a was detected
with alkaline phosphatase–conjugated goat anti–mouse IgG or goat anti–
mouse IgG2a (Southern Biotech), and absorbance at 405/630nm was com-
pared with known mouse IgG or IgG2a standards to quantitate.
Serum IFN-  ELISA. Serum was collected at the age of 17–18 wk for
TLR9, or at the time of death for TLR3 mice, and IFN-  was measured by
ELISA. Polystyrene plates were coated with monoclonal rat anti–mouse
IFN-  (PBL Biomedical Laboratories), blocked with 1% BSA in PBS, and
1:10 diluted serum was added. IFN-  was detected with rabbit anti–mouse
IFN-  (PBL Biomedical Laboratories) and alkaline phosphatase–conjugated
goat anti–rabbit IgG (Southern Biotech). Absorbance at 405/630nm was
compared with recombinant mouse IFN-  standard (PBL Biomedical Lab-
oratories) to quantitate. Limit of detection of the assay was 1.0 ng/ml in un-
diluted serum.
Analysis of kidney disease. Kidneys were bisected, and one half was
fixed in formalin and the other in paraformaldehyde (0.7% in PBS with
1.37% L-lysine and 0.2% sodium periodate). Paraformaldehyde-fixed kid-
neys were then dehydrated in 30% sucrose and flash-frozen in OCT. For-
malin-fixed kidneys were paraffin-embedded, sectioned, and hematoxylin
and eosin (H&E) or PAS stained (Histo-Scientific Research Laboratories).
Stained sections were scored for glomerular and interstitial disease by a renal
pathologist (M. Kashgarian) who was blinded to the genotype of the mice.
For IgG deposition, frozen kidneys from eight TLR9 /  and eight TLR9 / 
mice were sectioned and stained with biotin-conjugated goat anti–mouse
IgG (  chain specific; Southern Biotechnology Associates, Inc.) and AlexaTLR9 CONTROLS ANTI-DNA AUTOANTIBODIES | Christensen et al. 330
Fluor 647–conjugated streptavidin (Molecular Probes). For C3 deposition,
frozen kidney sections were stained with monoclonal rat anti–mouse C3
(Connex) and Alexa Fluor 647–conjugated goat anti–rat IgG (cross-
adsorbed against mouse IgG; Molecular Probes). Stained sections were read
on a fluorescent microscope at 400 , and images were captured with a
constant exposure time of 0.5 s. To quantitate IgG and C3 deposition,
mean fluorescence was calculated from captured images; two representative
glomeruli per mouse were outlined, and mean pixel intensity was calculated
with Photoshop (Adobe).
Online supplemental material. Fig. S1 shows the results of determina-
tions of anticardiolipin levels in sera from TLR9-deficient and intact mice,
using the assay described in Anticardiolipin ELISA section. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/
jem.20050338/DC1.
We thank Joe Craft, Ruslan Medzhitov, and Ann Marshak-Rothstein for helpful 
comments and discussions. We thank Marc Monestier for advice and positive control 
standards for the anticardiolipin assay. We thank Michelle Horniak, Kasie Stevens, 
Terrence Hunt, and the Yale Animal Resources Center staff for the expert animal care 
that made this work possible.
Sean Christensen was supported by National Institutes of Health (NIH)/National 
Institute of General Medical Sciences medical scientist training grant GM07205. 
These studies were supported by NIH grants R01 AI061090, P01 AR050256, 
and P01 AI36529.
The authors have no conflicting financial interests.
Submitted: 14 February 2005 
Accepted: 14 June 2005
REFERENCES
1. Notman, D.D., N. Kurata, and E.M. Tan. 1975. Profiles of antinuclear an-
tibodies in systemic rheumatic diseases. Ann. Intern. Med. 83:464–469.
2. Kotzin, B. 1996. Systemic lupus erythematosus. Cell. 85:303–306.
3. Plotz, P.H. 2003. The autoantibody repertoire: searching for order.
Nat. Rev. Immunol. 3:73–78.
4. Monestier, M., and B.L. Kotzin. 1992. Antibodies to histones in sys-
temic lupus erythematosus and drug-induced lupus syndromes. Rheum.
Dis. Clin. North Am. 18:415–436.
5. Hahn, B.H. 1998. Antibodies to DNA. N. Engl. J. Med. 338:1359–1368.
6. Egner, W. 2000. The use of laboratory tests in the diagnosis of SLE. J.
Clin. Pathol. 53:424–432.
7. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu.
Rev. Immunol. 21:335–376.
8. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the
adaptive immune responses. Nat. Immunol. 5:987–995.
9. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M.
Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000.
A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745.
10. Bernasconi, N.L., N. Onai, and A. Lanzavecchia. 2003. A role for
Toll-like receptors in acquired immunity: up-regulation of TLR9 by
BCR triggering in naive B cells and constitutive expression in memory
B cells. Blood. 101:4500–4504.
11. Leadbetter, E.A., I.R. Rifkin, A.M. Hohlbaum, B.C. Beaudette, M.J.
Shlomchik, and A. Marshak-Rothstein. 2002. Chromatin-IgG com-
plexes activate B cells by dual engagement of IgM and Toll-like recep-
tors. Nature. 416:603–607.
12. Viglianti, G.A., C.M. Lau, T.M. Hanley, B.A. Miko, M.J. Shlomchik,
and A. Marshak-Rothstein. 2003. Activation of autoreactive B cells by
CpG dsDNA. Immunity. 19:837–847.
13. Marshak-Rothstein, A., L. Busconi, C.M. Lau, A.S. Tabor, E.A. Leadbet-
ter, S. Akira, A.M. Krieg, G.B. Lipford, G.A. Viglianti, and I.R. Rifkin.
2004. Comparison of CpG s-ODNs, chromatin immune complexes, and
dsDNA fragment immune complexes in the TLR9-dependent activation
of rheumatoid factor B cells. J. Endotoxin Res. 10:247–251.
14. Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell. 2001.
Recognition of double-stranded RNA and activation of NF-kappaB
by Toll-like receptor 3. Nature. 413:732–738.
15. Kariko, K., H. Ni, J. Capodici, M. Lamphier, and D. Weissman. 2004.
mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem.
279:12542–12550.
16. Will, C.L., and R. Luhrmann. 2001. Spliceosomal UsnRNP biogene-
sis, structure and function. Curr. Opin. Cell Biol. 13:290–301.
17. Cohen, P.L., and R.A. Eisenberg. 1991. Lpr and gld: single gene mod-
els of systemic autoimmunity and lymphoproliferative disease. Annu.
Rev. Immunol. 9:243–269.
18. Izui, S., V.E. Kelley, K. Masuda, H. Yoshida, J.B. Roths, and E.D.
Murphy. 1984. Induction of various autoantibodies by mutant gene lpr
in several strains of mice. J. Immunol. 133:227–233.
19. Shlomchik, M.J., M.P. Madaio, D. Ni, M. Trounstine, and D. Huszar.
1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp.
Med. 180:1295–1306.
20. Ma, J., J. Xu, M.P. Madaio, Q. Peng, J. Zhang, I.S. Grewal, R.A. Fla-
vell, and J. Craft. 1996. Autoimmune lpr/lpr mice deficient in CD40
ligand: spontaneous Ig class switching with dichotomy of autoantibody
responses. J. Immunol. 157:417–426.
21. Tan, E.M., A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F.
Rothfield, J.G. Schaller, N. Talal, and R.J. Winchester. 1982. The
1982 revised criteria for the classification of systemic lupus erythemato-
sus. Arthritis Rheum. 25:1271–1277.
22. Emlen, W., and L. O’Neill. 1997. Clinical significance of antinuclear
antibodies: comparison of detection with immunofluorescence and en-
zyme-linked immunosorbent assays. Arthritis Rheum. 40:1612–1618.
23. Bradwell, A.R., R.P. Stokes, and G.D. Johnson, editors. 1995. Atlas of
Hep-2 Patterns. The Binding Site Ltd., Birmingham, UK. 118 pp.
24. Aarden, L.A., E.R. de Groot, and T.E. Feltkamp. 1975. Immunology
of DNA. III. Crithidia luciliae, a simple substrate for the determination
of anti-dsDNA with the immunofluorescence technique. Ann. NY
Acad. Sci. 254:505–515.
25. Isenberg, D.A., C. Dudeney, W. Williams, I. Addison, S. Charles, J.
Clarke, and A. Todd-Pokropek. 1987. Measurement of anti-DNA an-
tibodies: a reappraisal using five different methods. Ann. Rheum. Dis.
46:448–456.
26. Kavanaugh, A., R. Tomar, J. Reveille, D.H. Solomon, and H.A.
Homburger. 2000. Guidelines for clinical use of the antinuclear anti-
body test and tests for specific autoantibodies to nuclear antigens.
American College of Pathologists. Arch. Pathol. Lab. Med. 124:71–81.
27. Pettersson, I., M. Hinterberger, T. Mimori, E. Gottlieb, and J.A.
Steitz. 1984. The structure of mammalian small nuclear ribonucleopro-
teins. Identification of multiple protein components reactive with anti-
(U1)ribonucleoprotein and anti-Sm autoantibodies. J. Biol. Chem. 259:
5907–5914.
28. Bloom, D.D., J.L. Davignon, M.W. Retter, M.J. Shlomchik, D.S.
Pisetsky, P.L. Cohen, R.A. Eisenberg, and S.H. Clarke. 1993. V re-
gion gene analysis of anti-Sm hybridomas from MRL/Mp-lpr/lpr
mice. J. Immunol. 150:1591–1610.
29. Cocca, B.A., S.N. Seal, P. D’Agnillo, Y.M. Mueller, P.D. Katsikis, J.
Rauch, M. Weigert, and M.Z. Radic. 2001. Structural basis for au-
toantibody recognition of phosphatidylserine-beta 2 glycoprotein I and
apoptotic cells. Proc. Natl. Acad. Sci. USA. 98:13826–13831.
30. Arbuckle, M.R., M.T. McClain, M.V. Rubertone, R.H. Scofield, G.J.
Dennis, J.A. James, and J.B. Harley. 2003. Development of autoanti-
bodies before the clinical onset of systemic lupus erythematosus. N.
Engl. J. Med. 349:1526–1533.
31. Laderach, D., S. Koutouzov, J.F. Bach, and A.M. Yamamoto. 2003.
Concomitant early appearance of anti-ribonucleoprotein and anti-
nucleosome antibodies in lupus prone mice. J. Autoimmun. 20:161–170.
32. Shlomchik, M.J., J. Craft, and M.J. Mamula. 2001. From T to B and
back again: positive feedback in systemic autoimmune disease. Nat.
Rev. Immunol. 1:147–153.
33. Baechler, E.C., F.M. Batliwalla, G. Karypis, P.M. Gaffney, W.A. Ort-
mann, K.J. Espe, K.B. Shark, W.J. Grande, K.M. Hughes, V. Kapur, et
al. 2003. Interferon-inducible gene expression signature in peripheral
blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA.
100:2610–2615.JEM VOL. 202, July 18, 2005 331
ARTICLE
34. Bennett, L., A.K. Palucka, E. Arce, V. Cantrell, J. Borvak, J.
Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signa-
tures in systemic lupus erythematosus blood. J. Exp. Med. 197:711–723.
35. Lian, Z.X., K. Kikuchi, G.X. Yang, A.A. Ansari, S. Ikehara, and M.E.
Gershwin. 2004. Expansion of bone marrow IFN-alpha-producing
dendritic cells in New Zealand Black (NZB) mice: high level expres-
sion of TLR9 and secretion of IFN-alpha in NZB bone marrow. J. Im-
munol. 173:5283–5289.
36. Santiago-Raber, M.L., R. Baccala, K.M. Haraldsson, D. Choubey,
T.A. Stewart, D.H. Kono, and A.N. Theofilopoulos. 2003. Type-I in-
terferon receptor deficiency reduces lupus-like disease in NZB mice. J.
Exp. Med. 197:777–788.
37. Hron, J.D., and S.L. Peng. 2004. Type I IFN protects against murine
lupus. J. Immunol. 173:2134–2142.
38. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Toll-
like receptor 9–mediated recognition of Herpes simplex virus-2 by
plasmacytoid dendritic cells. J. Exp. Med. 198:513–520.
39. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo,
O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003.
Role of adaptor TRIF in the MyD88-independent toll-like receptor
signaling pathway. Science. 301:640–643.
40. Goeckeritz, B.E., M. Flora, K. Witherspoon, Q. Vos, A. Lees, G.J.
Dennis, D.S. Pisetsky, D.M. Klinman, C.M. Snapper, and J.J. Mond.
1999. Multivalent cross-linking of membrane Ig sensitizes murine B
cells to a broader spectrum of CpG-containing oligodeoxynucleotide
motifs, including their methylated counterparts, for stimulation of pro-
liferation and Ig secretion. Int. Immunol. 11:1693–1700.
41. Wang, Y., and A.M. Krieg. 2003. Synergy between CpG- or non-
CpG DNA and specific antigen for B cell activation. Int. Immunol. 15:
223–231.
42. Ishii, K.J., K. Suzuki, C. Coban, F. Takeshita, Y. Itoh, H. Matoba,
L.D. Kohn, and D.M. Klinman. 2001. Genomic DNA released by dy-
ing cells induces the maturation of APCs. J. Immunol. 167:2602–2607.
43. Boule, M.W., C. Broughton, F. Mackay, S. Akira, A. Marshak-Roth-
stein, and I.R. Rifkin. 2004. Toll-like receptor 9–dependent and –inde-
pendent dendritic cell activation by chromatin–immunoglobulin G
complexes. J. Exp. Med. 199:1631–1640.
44. Latz, E., A. Schoenemeyer, A. Visintin, K.A. Fitzgerald, B.G. Monks,
C.F. Knetter, E. Lien, N.J. Nilsen, T. Espevik, and D.T. Golenbock.
2004. TLR9 signals after translocating from the ER to CpG DNA in
the lysosome. Nat. Immunol. 5:190–198.
45. Casciola-Rosen, L.A., G. Anhalt, and A. Rosen. 1994. Autoantigens
targeted in systemic lupus erythematosus are clustered in two popula-
tions of surface structures on apoptotic keratinocytes. J. Exp. Med. 179:
1317–1330.
46. Mukae, N., H. Yokoyama, T. Yokokura, Y. Sakoyama, and S. Nagata.
2002. Activation of the innate immunity in Drosophila by endogenous
chromosomal DNA that escaped apoptotic degradation. Genes Dev. 16:
2662–2671.
47. Yoshida, H., Y. Okabe, K. Kawane, H. Fukuyama, and S. Nagata.
2005. Lethal anemia caused by interferon-beta produced in mouse em-
bryos carrying undigested DNA. Nat. Immunol. 6:49–56.
48. Cohen, P.L., R. Caricchio, V. Abraham, T.D. Camenisch, J.C. Jennette,
R.A. Roubey, H.S. Earp, G. Matsushima, and E.A. Reap. 2002. De-
layed apoptotic cell clearance and lupus-like autoimmunity in mice lack-
ing the c-mer membrane tyrosine kinase. J. Exp. Med. 196:135–140.
49. Manderson, A.P., M. Botto, and M.J. Walport. 2004. The role of
complement in the development of systemic lupus erythematosus.
Annu. Rev. Immunol. 22:431–456.
50. Sato, S., O. Takeuchi, T. Fujita, H. Tomizawa, K. Takeda, and S.
Akira. 2002. A variety of microbial components induce tolerance to li-
popolysaccharide by differentially affecting MyD88-dependent and
-independent pathways. Int. Immunol. 14:783–791.
51. Muzio, M., D. Bosisio, N. Polentarutti, G. D’Amico, A. Stoppacciaro,
R. Mancinelli, C. van’t Veer, G. Penton-Rol, L.P. Ruco, P. Allavena,
and A. Mantovani. 2000. Differential expression and regulation of toll-
like receptors (TLR) in human leukocytes: selective expression of
TLR3 in dendritic cells. J. Immunol. 164:5998-6004.
52. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T.
Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of
toll-like receptor 1-10 mRNA in cellular subsets of human peripheral
blood mononuclear cells and sensitivity to CpG oligodeoxynucle-
otides. J. Immunol. 168:4531–4537.
53. Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa.
2004. Innate antiviral responses by means of TLR7-mediated recogni-
tion of single-stranded RNA. Science. 303:1529–1531.
54. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S.
Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific
recognition of single-stranded RNA via toll-like receptor 7 and 8. Sci-
ence. 303:1526–1529.
55. Diebold, S.S., M. Montoya, H. Unger, L. Alexopoulou, P. Roy, L.E.
Haswell, A. Al-Shamkhani, R. Flavell, P. Borrow, and C. Reis e
Sousa. 2003. Viral infection switches non-plasmacytoid dendritic cells
into high interferon producers. Nature. 424:324–328.
56. Hoebe, K., E.M. Janssen, S.O. Kim, L. Alexopoulou, R.A. Flavell, J.
Han, and B. Beutler. 2003. Upregulation of costimulatory molecules
induced by lipopolysaccharide and double-stranded RNA occurs by
Trif-dependent and Trif-independent pathways. Nat. Immunol. 4:1223–
1229.
57. Balachandran, S., E. Thomas, and G.N. Barber. 2004. A FADD-
dependent innate immune mechanism in mammalian cells. Nature.
432:401–405.
58. Hardin, J.A. 2003. Directing autoimmunity to nucleoprotein particles:
the impact of dendritic cells and interferon   in lupus. J. Exp. Med.
197:681–685.
59. Amoura, Z., H. Chabre, S. Koutouzov, C. Lotton, A. Cabrespines, J.F.
Bach, and L. Jacob. 1994. Nucleosome-restricted antibodies are de-
tected before anti-dsDNA and/or antihistone antibodies in serum of
MRL-Mp lpr/lpr and  /  mice, and are present in kidney eluates of
lupus mice with proteinuria. Arthritis Rheum. 37:1684–1688.
60. Vlahakos, D.V., M.H. Foster, S. Adams, M. Katz, A.A. Ucci, K.J. Bar-
rett, S.K. Datta, and M.P. Madaio. 1992. Anti-DNA antibodies form
immune deposits at distinct glomerular and vascular sites. Kidney Int.
41:1690–1700.
61. Alba, P., L. Bento, M.J. Cuadrado, Y. Karim, M.F. Tungekar, I. Abbs,
M.A. Khamashta, D. D’Cruz, and G.R. Hughes. 2003. Anti-dsDNA,
anti-Sm antibodies, and the lupus anticoagulant: significant factors asso-
ciated with lupus nephritis. Ann. Rheum. Dis. 62:556–560.
62. Waters, S.T., M. McDuffie, H. Bagavant, U.S. Deshmukh, F. Gaskin, C.
Jiang, K.S. Tung, and S.M. Fu. 2004. Breaking tolerance to double
stranded DNA, nucleosome, and other nuclear antigens is not required for
the pathogenesis of lupus glomerulonephritis. J. Exp. Med. 199:255–264.
63. Chan, O.T., L.G. Hannum, A.M. Haberman, M.P. Madaio, and M.J.
Shlomchik. 1999. A novel mouse with B cells but lacking serum anti-
body reveals an antibody-independent role for B cells in murine lupus.
J. Exp. Med. 189:1639–1648.
64. Li, H., Y. Jiang, E.L. Prak, M. Radic, and M. Weigert. 2001. Editors
and editing of anti-DNA receptors. Immunity. 15:947–957.
65. Rakoff-Nahoum, S., J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R.
Medzhitov. 2004. Recognition of commensal microflora by toll-like
receptors is required for intestinal homeostasis. Cell. 118:229–241.
66. Boes, M., T. Schmidt, K. Linkemann, B.C. Beaudette, A. Marshak-
Rothstein, and J. Chen. 2000. Accelerated development of IgG au-
toantibodies and autoimmune disease in the absence of secreted IgM.
Proc. Natl. Acad. Sci. USA. 97:1184–1189.
67. Coulie, P., and J. Van Snick. 1983. Rheumatoid factors and secondary
immune responses in the mouse. I. Frequent occurrence of hybridomas
secreting IgM anti-IgG1 autoantibodies after immunization with pro-
tein antigens. Eur. J. Immunol. 13:895.
68. Clarkson, A.B., Jr., and G.H. Mellow. 1981. Rheumatoid factor-like
immunoglobulin M protects previously uninfected rat pups and dams
from Trypanosoma lewisi. Science. 214:186–188.